LBA-08Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer
2015
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
14
Citations
NaN
KQI